Nurse Practitioners Encouraged To Take A Leading Role In Treating Hypertensive Patients
Friday, April 24th, 2009
InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), has announced that RESPeRATE - the only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertension - is highlighted as an effective treatment for high blood pressure in the April issue of the Journal of the American Academy of Nurse Practitioners.